#16
|
||||
|
||||
Âîò è åùå íîâîñòè â ñîêðàùåííîì âèäå ( äàéäæåñò åæåäíåâíûé îò àññîöèàöèè ýíäîêðèíîëîãîâ , ëåíü ïåðåâîäèòü )
Vitamins Associated With Increased Risk Of Death In Older Women. ABC World News (10/10, lead story, 2:40, Sawyer) added, "A major new study in an important medical journal finds in some cases the supplements either do no good or could increase the risk of dying from cancer or heart disease." NBC Nightly News (10/10, lead story, 2:40, Williams) reported that the study published in the Archives of Internal medicine found that "women who take supplements, including multivitamins, appear to have slightly higher death rates." NBC chief science correspondent Robert Bazell explained, "Researchers followed more than 38,000 women average age 61 for 19 years. They found higher death rates in those taking multivitamins, vitamin B-6, folic acid, zinc, magnesium, copper and iron." In a follow-on analysis piece, NBC Nightly News (10/10, story 2, 1:20, Williams) discussed the story with NBC medical director Dr. Tanya Benenson, who told viewers, "I think a multivitamin for anybody is fine. ... It's when we get into excessive mega doses of things when you're not deficient, that's where the problem starts." She added, "Just because a little bit is good for you doesn't mean more is better." On the front of its Personal Journal section, the Wall Street Journal (10/11, D1, Dooren, Subscription Publication) points out that investigators followed some 39,000 women for approximately 19 years. The New York Times (10/10, D6, Bakalar, Subscription Publication) reports in "Vital Signs" that "some supplements, like iron, were associated with a substantial increase in the risk of death, while others -- vitamin A and vitamin D, for example -- had no effect." Overall, "multivitamin use was linked to a 2.4 percent increase in the absolute risk of death, but calcium supplements appeared to decrease the risk."
__________________
Ã.À. Ìåëüíè÷åíêî |
#17
|
||||
|
||||
(ñî ñëåçàìè íà ãëàçàõ)
ÁÀÄ - àááðåâèàòóðà æåíñêîãî ðîäà, íå ñêëîíÿåòñÿ.
__________________
Ñ óâàæåíèåì, Îëüãà Èâàíîâíà Áåëîâåæåö |
#18
|
||||
|
||||
Îìàêîð - åäèíñòâåííûé ïîëåçíàÿ ÁÀÄ, äà è òî â ñòðîãî îãîâîðåííûõ ñèòóàöèÿõ. Ïî ìîåìó åãî óæå â ëåêàðñòâà ïîâûñèëè. Ôèðìà-ïðîèçâîäèòåëü ó ìåíÿ äîâåðèÿ íå âûçûâàåò. ß ëè÷íî çà ìîðñêóþ ðûáó.
|
#19
|
||||
|
||||
__________________
Ã.À. Ìåëüíè÷åíêî |
#20
|
||||
|
||||
Ëîâàçà (ýêñ-Îìàêîð) - ïàòåíòîâàííàÿ ñìåñü ýôèðîâ îìåãà-3 æèðíûõ êèñëîò, êîòîðàÿ â êëèíè÷åñêîì òðàéëå COMBOS (à ìîæåò è äðóãèõ) ïîêàçàëà ñâîþ ýôôåêòèâíîñòü è ïîýòîìó êîìïàíèÿ Reliant èëè ÃÑÊ, ïåðåêóïèâøàÿ åå, ïðîâåëè åå ÷åðåç ÔÄÀ è çàðåãèñòðèðîâàëè êàê ëåêàðñòâî. Ëþáîé äðóãîé ïðîèçâîäèòåëü îìåãè-3 ìîæåò ýòî ñäåëàòü, åñëè áóäåò è íèõ íà òî æåëàíèå è äåíüãè, íî áîëüøèíñòâî ïðåäïî÷èòàåò ñòðàòåãèþ "me too": âûïóñêàÿ àíàëîãè÷íûé ïðîäóêò, ãîâîðÿò: ïîìíèòå ðåçóëüòàòû ñ îìàêîðîì, òàê âîò ó íàñ òàêîé æå ýôôåêò îò íàøåãî ïðîäóêòà, òê òîæå ñîäåðæèò îìåãà-3...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#21
|
||||
|
||||
À ïî÷åìó èìåííî òîëüêî îìàêîð?
À êàê æå äðóãèå Îìåãà-3 è ïî÷åìó: Àòåðîáëîê; Àðòåðîäèåò; Áèîàêòèâ Ìàðèí Ïëþñ; Âèòðóì Êàðäèî Îìåãà-3; Äîêîçàãåêñàåíîâàÿ êèñëîòà; Äîïïåëüãåðö àêòèâ Îìåãà-3; Îêåàíîë; Îìåãà-3; Îìåãà-3 ïëþñ; Îìåãà-3 Ôîðòåêñ; Îìåãàíîë; Ïåðôîïòèì Îìåãà-3; Ðûáèé æèð; Ñåâåí ñèç; Òàíäåìàêñ; Ýéêîçàïåíòàåíîâàÿ êèñëîòà; Ýéêîíîë; Ýïàìàð Ñòðîíã ???
__________________
Àëåêñàíäð Èâàíîâè÷ ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ |
#22
|
||||
|
||||
Àëåêñàíäð Èâàíîâè÷,
ïîçâîëüòå óòî÷íèòü: ÷òî èìåííî ïî÷åìó - ïîëåçåí èëè ïðîèçâåäåí â ëåêàðñòâî?
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
|
#23
|
||||
|
||||
Öèòàòà:
Íà ÷åì èìåííî ïðîâîäèëèñü èññëåäîâàíèÿ òèïà COMBOS ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]) è GISI Prevenzione ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]) äîïîäëèííî íå èçâåñòíî, ò.ê. â îò÷åòàõ òîðãîâûå íàçâàíèÿ íå ïðåäñòàâëåíû âîâñå. Ïî÷åìó-òî äóìàþ, ÷òî èìåííî îìàêîð òóò ñîâñåì íå ïðè ÷åì
__________________
Àëåêñàíäð Èâàíîâè÷ ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ |
#24
|
||||
|
||||
íå çíàþ, êàêèå ïðåòåíçèè ê ïðîèçâîäèòåëþ Ëîâàçû/Îìàêîðà - åå ñ 2007 ïðîèçâîäÿò ÃëàêñîÑìèòÊëÿéí
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#25
|
||||
|
||||
Öèòàòà:
Ïî÷åìó ïîëåçíû Îìåãà-3 ÿ äîãàäûâàþñü Ïî÷åìó, êòî è êàê ðåãèñòðèðóåò ïðåïàðàòû - òîæå äîãàäûâàþñü. Âîïðîñ áûë ïî÷åìó èìåííî îìàêîð, à íå, äîïóñòèì, "Ïåðôîïòèì Îìåãà-3" (òêíóë ïàëüöåì, ÷òîáû èçáåæàòü ïðåäâçÿòîñòè)?
__________________
Àëåêñàíäð Èâàíîâè÷ ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ |
#26
|
||||
|
||||
__________________
Àëåêñàíäð Èâàíîâè÷ ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ |
#27
|
||||
|
||||
Öèòàòà:
äåéñòâèòåëüíî íå çíàþ, ÷òî èìåííî çà Îìàêîð â Ðîññèè, ïîäóìàë, ÷òî îäíî è òîæå, ÷òî áûëî çäåñü äî 2007
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#28
|
||||
|
||||
Âîò ÷òî íàøåë ïî ñìåíå èìåíè:
OMACOR is changing to LOVAZA. New name, new NDC#s, but it is the same medication. Why is the name changing? • Patient safety is of utmost importance • Reliant Pharmaceuticals is taking this step at the request of the FDA in response to a limited number of prescribing and dispensing errors due to similarity in the name between OMACOR and Amicar Same efficacy, safety and tolerability • Size, strength and ingredients of the OMACOR gel capsule will remain unchanged. Only the name and NDC#s are changing When? • LOVAZA will begin shipping mid-July. Please sell through existing OMACOR until stock is exhausted or if you have a specific prescription for LOVAZA • Reliant will begin marketing to physicians and industry August 1, 2007 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ñîâïàäàåò ïî äàòå ñ ïðèîáðåòåíèåì Reliant Pharmaceuticals êîìïàíèåé ÃÑÊ, òàê ÷òî íå òîëüêî èç-çà ïóòàíèöû ñ àìèíîêàïðîíêîé, íî è äëÿ âûõîäà íà ìèðîâîé ðûíîê âî èçáåæàíèå ïóòàíèöû ñ àááîòîâñêèì Îìàêîðîì
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#29
|
||||
|
||||
îòêîïàë âîò òàêîé àãèò-ëèñòîê:
When to take statins; Lovaza versus OTC fish oil supplements. DeDea L. JAAPA. 2011 May;24(5):23.  Ëîâàçå (1 ã êàïñóëà) 840 ìã îìåãà-3, òîãäà êàê áåçðåöåïòóðíûå áèîäîáàâêè îìåãè ìîãóò ñîäåðæàòü ðàçíîå êîëè÷åñòâî îìåã... â Ëîâàçå íåò ðòóòè, òÿæåëûõ ìåòàëëîâ äèîêñèíà, òîãäà êàê â áèîäîáàâêàõ îíè áûâàþò è èõ óðîâåíü íåèçâåñòåí... â Øòàòàõ ëîâàçà ñåðòèôèöèðîâàíà òîëüêî äëÿ êîððåêöèè ãèïåðòðèãëèöåðèäåìèè (4 êàïñóëû â äåíü), òî åñòü îíà íå ïðåäëàãàåòñÿ äëÿ ïðîôèëàêòèêè ÑÑÇ, èáî òàêîãî òðàéëà ñ íåé íå áûëî, íåñìîòðÿ íà GISSI, JeLIS ect.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#30
|
||||
|
||||
Öèòàòà:
Áûâàåò îäíî ëåêàðñòâî îò îäíîé ôèðìû â ðàçíûõ ñòðàíàõ íàçûâàåòñÿ ïî ðàçíîìó (àòîðâàñòàòèí îò Ôàéçåðà: ëèïèòîð, ëèïðèìàð, ñîðòèñ). À áûâàåò îäíî íàçâàíèå â ðàçíûõ ñòðàíàõ çàðåãèñòðèðîâàíî äëÿ ðàçíûõ ëåêàðñòâ. Òóò îäíî íàçâàíèå, ñîñòàâ î÷åíü ïîõîæèé, íî ïðîèçâîäèòåëè ðàçíûå. Èëè âñå-òàêè èç îäíîé áî÷êè? P.S. Ëîâàçà. Each 1-gram capsule of LOVAZA contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg). LOVAZA capsules also contain the following inactive ingredients: 4 mg α-tocopherol (in a carrier of soybean oil), and gelatin, glycerol, and purified water (components of the capsule shell). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Îìàêîð. Êàïñóëû ìÿãêèå æåëàòèíîâûå, ïðîçðà÷íûå, ðàçìåð 20; ñîäåðæèìîå êàïñóë - ìàñëÿíèñòàÿ æèäêîñòü ñâåòëî-æåëòîãî öâåòà. 1 êàïñ. ýòèëîâûå ýôèðû îìåãà-3 êèñëîò 1 ã, â ò.÷. ýòèëîâûé ýôèð ýéêîçàïåíòàåíîâîé êèñëîòû (ÝÏÊ) 46% ýòèëîâûé ýôèð äîêîçàãåêñàåíîâîé êèñëîòû (ÄÃÊ) 38% Âñïîìîãàòåëüíûå âåùåñòâà: α-òîêîôåðîë 4 ìã. Ñîñòàâ îáîëî÷êè êàïñóëû: æåëàòèí, ãëèöåðîë, âîäà î÷èùåííàÿ. 28 øò. - ôëàêîíû ïîëèýòèëåíîâûå. 100 øò. - ôëàêîíû ïîëèýòèëåíîâûå.
__________________
Àëåêñàíäð Èâàíîâè÷ ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ |